BlossomHill Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- BlossomHill Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BLSM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001839970
- EIN
- 85-1578711
Board of directors
- Since 2026
- Since 2026
-
Jingrong Jean Cui · Director · President and CEOSince 2026
- Since 2026
-
Sheila Gujrathi · DirectorSince 2026
-
Sundeep Agrawal · DirectorSince 2026
-
Yishan Li · Director · Executive ChairmanSince 2026
Chief executives
Jingrong Jean Cui
· President and CEO
Since August 2026
Board connections
5 of this board's directors also sit on 18 other boards.
- via Bihua Chen and John P. Schmid
- via Bihua Chen and John P. Schmid
- via Carl L. Gordon
- via John P. Schmid
- via Carl L. Gordon
- via Bihua Chen
- via Carl L. Gordon
- via John P. Schmid
- via Carl L. Gordon
- via Bihua Chen
- via John P. Schmid
- via Sheila Gujrathi
- via Carl L. Gordon
- via Carl L. Gordon
- via Sundeep Agrawal
- via Sheila Gujrathi
- via Carl L. Gordon
- via John P. Schmid
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $25,181,900
- 7 purchases by 6 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Sundeep Agrawal Director | Derivative conversion | +578,524 | — | — |
| Aug 10, 2026 | Bihua Chen Director, 10% owner | Derivative conversion | +1,599,993 | — | — |
| Aug 10, 2026 | John P. Schmid Director | Open-market purchase | +6,000 | $16.00 | $96,000 |
| Aug 10, 2026 | Jason A. Keyes Officer (Chief Financial Officer) | Open-market purchase | +700 | $16.00 | $11,200 |
| Aug 10, 2026 | Yishan Li Director, Officer (Executive Chairman), 10% owner | Derivative conversion | +1,600,682 | — | — |
| Aug 10, 2026 | Jingrong Jean Cui Director, Officer (President and CEO), 10% owner | Derivative conversion | +1,600,682 | — | — |
| Aug 10, 2026 | ORBIMED ADVISORS LLC Director | Derivative conversion | +1,039,996 | — | — |
| Aug 10, 2026 | Carl L. Gordon Director | Derivative conversion | +1,039,996 | — | — |
| Aug 10, 2026 | Bihua Chen Director, 10% owner | Derivative conversion | +1,701,541 | — | — |
| Aug 10, 2026 | Yishan Li Director, Officer (Executive Chairman), 10% owner | Derivative conversion | +113,435 | — | — |
| Aug 10, 2026 | Jingrong Jean Cui Director, Officer (President and CEO), 10% owner | Derivative conversion | +113,435 | — | — |
| Aug 10, 2026 | Liptak Vincent Paul Officer (General Counsel) | Open-market purchase | +2,200 | $16.00 | $35,200 |
| Aug 10, 2026 | ORBIMED ADVISORS LLC Director | Derivative conversion | +1,049,283 | — | — |
| Aug 10, 2026 | Carl L. Gordon Director | Derivative conversion | +1,049,283 | — | — |
| Aug 10, 2026 | Bihua Chen Director, 10% owner | Open-market purchase | +312,500 | $16.00 | $5,000,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.